Literature DB >> 18322650

Regulatory mechanisms of atrial fibrotic remodeling in atrial fibrillation.

C-S Lin1, C-H Pan.   

Abstract

Electrical, contractile and structural remodeling have been characterized in atrial fibrillation (AF), and the latter is considered to be the major contributor to AF persistence. Recent data show that interstitial fibrosis can predispose to atrial conduction impairment and AF induction. The interplay between cardiac matrix metalloproteinases (MMPs) and their endogenous inhibitors, tissue inhibitors of MMPs (TIMPs), is thought to be critical in atrial extracellular matrix (ECM) metabolism. At the molecular level, angiotensin II, transforming growth factor-beta1, inflammation and oxidative stress are particularly important for ECM dysregulation and atrial fibrotic remodeling in AF. Therefore, we review recent advances in the understanding of the atrial fibrotic process, the major downstream components in this remodeling process, and the expression and regulation of MMPs and TIMPs. We also describe the activation of bioactive molecules in both clinical studies and animal models to modulate MMPs and TIMPs and their effects on atrial fibrosis in AF.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18322650     DOI: 10.1007/s00018-008-7408-8

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  38 in total

Review 1.  Atrial remodeling, fibrosis, and atrial fibrillation.

Authors:  José Jalife; Kuljeet Kaur
Journal:  Trends Cardiovasc Med       Date:  2014-12-31       Impact factor: 6.677

2.  Cardiac fibrosis as a determinant of ventricular tachyarrhythmias.

Authors:  Norishige Morita; William J Mandel; Yoshinori Kobayashi; Hrayr S Karagueuzian
Journal:  J Arrhythm       Date:  2014-12-01

3.  Inflammatory responses in the atria: should they stay or should they go?

Authors:  Heather S Duffy
Journal:  Heart Rhythm       Date:  2010-11-05       Impact factor: 6.343

Review 4.  Immunopathogenesis and biomarkers of recurrent atrial fibrillation following ablation therapy in patients with preexisting atrial fibrillation.

Authors:  John H Rosenberg; John H Werner; Gilman D Plitt; Victoria V Noble; Jordan T Spring; Brooke A Stephens; Aleem Siddique; Helenmari L Merritt-Genore; Michael J Moulton; Devendra K Agrawal
Journal:  Expert Rev Cardiovasc Ther       Date:  2018-12-29

Review 5.  The cardiomyocyte circadian clock: emerging roles in health and disease.

Authors:  David J Durgan; Martin E Young
Journal:  Circ Res       Date:  2010-03-05       Impact factor: 17.367

6.  Cardiac Arrhythmia: In vivo screening in the zebrafish to overcome complexity in drug discovery.

Authors:  Calum A Macrae
Journal:  Expert Opin Drug Discov       Date:  2010-07       Impact factor: 6.098

7.  Effects of spironolactone on atrial structural remodelling in a canine model of atrial fibrillation produced by prolonged atrial pacing.

Authors:  J Zhao; J Li; W Li; Y Li; H Shan; Y Gong; B Yang
Journal:  Br J Pharmacol       Date:  2010-01-15       Impact factor: 8.739

Review 8.  New pharmacological strategies for the treatment of atrial fibrillation.

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Ann Noninvasive Electrocardiol       Date:  2009-07       Impact factor: 1.468

Review 9.  Mechanisms of arrhythmias and conduction disorders in older adults.

Authors:  Mahek Mirza; Anton Strunets; Win-Kuang Shen; Arshad Jahangir
Journal:  Clin Geriatr Med       Date:  2012-11       Impact factor: 3.076

10.  Plasma profiles of matrix metalloproteinases and tissue inhibitors of the metalloproteinases predict recurrence of atrial fibrillation following cardioversion.

Authors:  Rupak Mukherjee; Joseph G Akar; J Marcus Wharton; Deborah K Adams; Catherine D McClure; Robert E Stroud; Allison D Rice; Stacia M DeSantis; Francis G Spinale; Michael R Gold
Journal:  J Cardiovasc Transl Res       Date:  2013-05-31       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.